Prolia (denosumab)

P=N/A, N=200, Not yet recruiting, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University; West China Hospital, SCU

P=N/A, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P=N/A, N=188, Recruiting, Hebei Medical University Third Hospital; Hebei Medical University Third Hospital

P4, N=250, Not yet recruiting, The First Affiliated Hospital of Chongqing Medical University; No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

A 67-year-old male patient with advanced rectal cancer and multiple metastases received chemotherapy with oxaliplatin and capecitabine, targeted therapy with bevacizumab, denosumab for bone metastases, and local radiotherapy. However, when the condition deteriorated and the number of metastatic lesions increased, the expression levels of myocardial enzymes sharply rose again, eventually accompanying the patient's death. The non-cardiac injury-related increase in myocardial enzymes is closely associated with tumor burden and cancer activity, and can serve as a dynamic indicator for evaluating the efficacy of radiotherapy and chemotherapy and disease progression.

Soft tissue recurrence in GCTB may occur independently or following intraosseous recurrence and is frequently observed in high-grade lesions. Although not statistically significant, the findings suggest a possible association between tumor aggressiveness and STR. Histological features remain consistent with osseous lesions, but the diagnostic value of H3F3A expression in STRs warrants fur ther investigation. Importantly, STR represents a distinct recurrence pattern and may be associated with an increased risk of pulmonary metastasis, underscoring the need for vigilant long-term follow-up and systematic surveillance.   Cite this article as: Mirioğlu A, Dalkır KA, Ölke HC, et al. Soft tissue recurrence in giant cell tumor of bone: risk factors and radiological and histopathological features. Acta Orthop Traumatol Turc.,  2025;59(6):470-476.

He received capmatinib (800 mg/day) and denosumab, with SBRT to vertebral metastases and later to the primary lung tumor. Temporary suspension of capmatinib during SBRT, along with careful monitoring, optimized tolerability, and outcomes. This case supports the feasibility and potential synergy of precision multimodal therapy in MET-driven oligometastatic NSCLC, highlighting the need for further prospective studies.

P4, N=36, Not yet recruiting, Western Sydney Local Health District

Initial management included aggressive intravenous hydration and administration of denosumab to control the symptomatic hypercalcemia, which resulted in improved calcium levels and renal function. Further evaluation with imaging, including parathyroid ultrasound and Technetium-99m (Tc-99m) sestamibi scintigraphy, was consistent with a right parathyroid adenoma. The patient subsequently underwent parathyroidectomy, and histological analysis confirmed the diagnosis of parathyroid carcinoma.

P2, N=15, Completed, National Institute of Dental and Craniofacial Research (NIDCR) | Active, not recruiting --> Completed

There is only one other case that has been documented of a β-hCG-producing GCTBoccurring in the base of the skull with secondary aneurysmal bone cyst-like changes.This appears to be the first reported instance of β-hCG-secreting GCTB in the gnathicbones. This case exemplifies the diagnostic challenges of rare presentations of GCTBand alerts clinicians to the potential misleading presentation of hormone expression.

Therefore, expert consensus suggests initiating bisphosphonate treatment after denosumab discontinuation, even though there is no an optimal bisphosphonate regimen. There are numerous open research questions which future prospective studies will have to answer in order to personalize the most appropriate antiresorptive therapy for each patient.